Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Altimmune, Inc. (ALT : NSDQ)

• Company Description    Altimmune, Inc. is a clinical-stage immunotherapeutics company. It focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease. The company's proprietary platform technologies consist of RespirVec and Densigen. Altimmune Inc., formerly known as Pharmathene Inc., is based in Gaithersburg, United States. Number of Employees: 59

• Price / Volume Information    Yesterday's Closing Price: $5.28 Daily Weekly Monthly 20 Day Moving Average: 3,489,868 shares Shares Outstanding: 104.34 (millions) Market Capitalization: $550.93 (millions) Beta: -0.03 52 Week High: $8.88 52 Week Low: $2.90 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 26.01% 23.35% 12 Week 33.33% 30.93% Year To Date -26.77% -36.81%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 910 CLOPPER ROAD SUITE 201S - GAITHERSBURG,MD 20878 USA ph: 240-654-1450 fax: 410-269-2601 reisenstadt@altimmune.com http://www.altimmune.com

• General Corporate Information    Officers Vipin K. Garg - President; Chief Executive Officer and Director Mitchel Sayare - Chairman Gregory Weaver - Chief Financial Officer John Gill - Director Philip Hodges - Director Peer Information Altimmune, Inc. (GSAC) Altimmune, Inc. (CASI) Altimmune, Inc. (ALCD.) Altimmune, Inc. (OMNN) Altimmune, Inc. (CGPI.) Altimmune, Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 02155H200 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 02/26/26 Share - Related Items Shares Outstanding: 104.34 Most Recent Split Date: 9.00 (0.03:1) Beta: -0.03 Market Capitalization: $550.93 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.25 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.99 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 02/26/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.72 Price/Cash Flow: - Price / Sales: 27,546.29 EPS Growth vs. Year Ago Period: 34.38% vs. Previous Quarter: 22.22% Sales Growth vs. Year Ago Period: 0.00% vs. Previous Quarter: 0.00% ROE 09/30/25 - -54.79 06/30/25 - -62.63 03/31/25 - -65.44 ROA 09/30/25 - -47.59 06/30/25 - -55.29 03/31/25 - -58.43 Current Ratio 09/30/25 - 17.18 06/30/25 - 20.44 03/31/25 - 15.85 Quick Ratio 09/30/25 - 17.18 06/30/25 - 20.44 03/31/25 - 15.85 Operating Margin 09/30/25 - -419,575.00 06/30/25 - -438,730.03 03/31/25 - -451,200.00 Net Margin 09/30/25 - -419,575.00 06/30/25 - -438,730.03 03/31/25 - -451,200.00 Pre-Tax Margin 09/30/25 - -422,980.03 06/30/25 - -442,135.00 03/31/25 - -454,604.97 Book Value 09/30/25 - 1.94 06/30/25 - 1.99 03/31/25 - 1.85 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - 0.08 06/30/25 - 0.09 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - 7.22 06/30/25 - 8.16 03/31/25 - 0.00

Powered by Zacks Investment Research ©